SELENINOTRIGLICERYDY NADZIEJĄ W ZWALCZANIU NOWOTWORÓW

Anna Flis-Borsuk, Lidia Śliwka, Zofia Suchocka, Jakub Borsuk, Zbigniew Fijałek, Katarzyna Lubelska, Piotr Suchocki

Bibliografia

1.    Fairweather-Tait S. J., Bao Y., Broadley M. R., Collings R., Ford D., Hesketh J. E., Hurst R. Selenium in human health and disease. Antioxid Redox Signal, 2011, 14(7), 1337-1383.

2.    Rayman M. P. Selenium and human health. Lancet, 2012, 379(9822), 1256-1268.

3.    Brown K. M., Arthur J. R. Selenium, selenoproteins and human health: a review. Public Health Nutr, 2001, 4(2b), 593-599.

4.    Madison T.C. Sanitary report – Fort Randall. In Statistical Report on the Sickness and Mortality in the Army of the United States (Coolidge, R.H., ed.). 36th Congress Senate Exchange Document, 1860, 37-41.

5.    Schwarz K., Foltz C. M. Factor 3 activity of selenium compounds. J. Biol. Chem., 1958, 233, 245–251.

6.    Combs G. F., Gray W. P. Food system-based approaches to improving micronutrient nutrition: the case for selenium. Biofactors, 2000, 12(1-4), 39-43.

7.    Lu J., Holmgren A. Selenoproteins. J Biol Chem, 2009, 284(2), 723-727.

8.    Clark L. C., Dalkin B., Krongrad A., Combs G. F., Jr., Turnbull B. W., Slate E. H., Witherington R., Herlong J. H., Janosko E., Carpenter D., Borosso C., Falk S., Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol, 1998, 81(5), 730-734.

9.    Blankenberg S., Rupprecht H. J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., Lackner K. J. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med, 2003, 349(17), 1605-1613.

10.  Rederstorff M., Krol A., Lescure A. Understanding the importance of selenium and selenoproteins in muscle function. Cell Mol Life Sci, 2006, 63(1), 52-59.

11.  Hatfield D. L., Berry M. J., Gladyshev V. N. Selenium: Its Molecular Biology and Role in Human Health. Springer Science+Business Media, 2012.

12.  Baum M. K., Campa A. Role of selenium in HIV/AIDS. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium – its molecular biology and role in human health. New York: Springer, 2006, 299-310.

13.  Broome C. S., McArdle F., Kyle J. A., Andrews F., Lowe N. M., Hart C. A., Arthur J. R., Jackson M. J. An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr, 2004, 80(1), 154-162.

14.  Rayman M. P., Infante H. G., Sargent M. Food-chain selenium and human health: spotlight on speciation. Br J Nutr, 2008, 100(2), 238-253.

15.  Fitak B. A., Grabowski M., Suchocki P. Preparat przeciwnowotworowy i sposób jego wytwarzania. Pol Patent, 1999, 1765301994.

16.  Suchocki P., Jakoniuk D., Fitak B.A. Specific spectrophotometric method with trifluoroacetic acid for the determination of selenium(IV) in selenitetriglycerides. J Pharm Biomed Anal, 2003, 32, 1029-1036.

17.  Jastrzebski Z., Czyzewska-Szafran H., Remiszewska M., Fijalek Z., Fitak B. A., Suchocki P. Pharmacokinetics of selol, a new agent containing selenium, in rats. Drugs Exp Clin Res, 1997, 23(1), 7-11.

18.  Jastrzebski Z., Czyzewska-Szafran H., Fijatek Z., Suchocki P., Fitak B. A. Toxicity studies of a new selenium compound, Selol, in rats. Drugs Exp Clin Res, 1995, 21(6), 217-220.

19.  Rahden-Staron I., Suchocki P., Czeczot H. Evaluation of mutagenic activity of the organo-selenium compound Selol by use of the Salmonella typhimurium mutagenicity assay. Mutat Res, 2010, 699(1-2), 44-46.

20.  Schafer F. Q., Buettner G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med, 2001, 30(11), 1191-1212.

21.  Hutter D. E., Till B. G., Greene J. J. Redox state changes in density-dependent regulation of proliferation. Exp Cell Res, 1997, 232(2), 435-438.

22.  Stipanuk M. H., Ueki I., Dominy J. E., Jr., Simmons C. R., Hirschberger L. L. Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. Amino Acids, 2009, 37(1), 55-63.

23.  Brait M., Ling S., Nagpal J. K., Chang X., Park H. L., Lee J., Okamura J., Yamashita K., Sidransky D., Kim M. S. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One, 2012, 7(9), e44951.

24.  Sies H. Strategies of antioxidant  defense Eur. J. Biochem. , 1993, 215, 213-219.

25.  Carocho M., Ferreira I. C. A review on antioxidants, prooxidants and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol, 2013, 51, 15-25.

26.  Lushchak V. I. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids, 2012, 2012, 736837.

27.  Stańczyk M., Jaworska M., Wilk M., Suchocki P., Anuszewska E. The effect of selenium on redox state and thiols changes in lung tissue after Selol, a new organoselenium (IV) compound, administration. Central European Journal of Immunology, 2010, 35(3), 115-122.

28.  Suchocki P., Misiewicz I., Skupinska K., Waclawek K., Fijalek Z., Kasprzycka-Guttman T. The activity of Selol in multidrug-resistant and sensitive human leukemia cells. Oncol Rep, 2007, 18(4), 893-899.

29.  Suchocki P., Misiewicz-Krzeminska I., Skupinska K., Niedzwiecka K., Lubelska K., Fijalek Z., Kasprzycka-Guttman T. Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacol Rep, 2010, 62(2), 352-361.

30.  Curtis D., Klaassen John B., Watkins III, redakcja wydania I polskiego: Barbara Zielińska-Psuja, Andrzej Sapota. Podstawy toksykologii. Casarett & Doull 2014 ISBN: 978-83-7846-058-9, 149-165.

31.  Dudkiewicz-Wilczyńska J., Książek I., Nowak K., Suchocki P., Flis S., Kiljan M., Anuszewska M. Study of the effect of Selol and sodium selenite on HeLa cells in vitro. Chemik, 2011, 65(2), 105-114.

32.  Ksiazek I., Sitarz K., Anuszewska E., Dudkiewicz-Wilczyńska J., Roslon M., Koronkiewicz M., Suchocki P. TOXICITY STUDIES OF SELOL – AN ORGANIC SELENIUM (IV) COMPOUND- IN VITRO RESEARCH International Journal of Pharmacy and Pharmaceutical Sciences 2014, 6(5), 264-269.

33.  Ślusarczyk J., Dudek M., Wierzbicka M., Suchocki P., Kuraś M. Antimitotic effect of Selol and sodium selenate (IV) on Allium test cells. Caryologia, 2014, 67(3), 250-259.

34.  Wojciechowska U., Didkowska J. Poprawa przeżyć chorych na nowotwory złośliwe w Polsce. Analiza przeżyć pacjentów zdiagnozowanych w latach 2003–2005. Nowotwory. Journal of Oncology, 2013, 63(4), 279-285.

35.  El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res, 2001, 475(1-2), 123-139.

36.  Ksiazek I., Sitarz K., Roslon M., Anuszewska E., Suchocki P., Wilczynska J. D. The influence of Selol on the expression of oxidative stress genes in normal and malignant prostate cells. Cancer Genomics Proteomics, 2013, 10(5), 225-232.

37.  Flis A., Suchocki P., Królikowska M., Suchocka Z., Remiszewska M., Śliwka L., Książek I., Sitarz K., Sochacka M., Hoser G., Anuszewska E., Wroczyński P., Jastrzębski Z. Selenitetriglycerides—Redox-active agents. Pharmacological Reports, 2015, 67(1), 1-8.

38.  Nguyen T., Sherratt P. J., Nioi P., Yang C. S., Pickett C. B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem, 2005, 280(37), 32485-32492.

39.  Driscoll D. M.,Copeland P. R. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr, 2003, 23, 17-40.

40.  Hatfield D. L., Gladyshev V. N. How selenium has altered our understanding of the genetic code. Mol Cell Biol, 2002, 22(11), 3565-3576.

41.  Lee B. J., Worland P. J., Davis J. N., Stadtman T. C., Hatfield D. L. Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon, UGA. J Biol Chem, 1989, 264(17), 9724-9727.

42.  Miniard A. C., Middleton L. M., Budiman M. E., Gerber C. A., Driscoll D. M. Nucleolin binds to a subset of selenoprotein mRNAs and regulates their expression. Nucleic Acids Res, 2010, 38(14), 4807-4820.

43.  Sochacka M., Giebultowicz J., Remiszewska M., Suchocki P., Wroczynski P. Effects of Selol 5% supplementation on the activity or concentration of antioxidants and malondialdehyde level in the blood of healthy mice. Pharmacol Rep, 2014, 66(2), 301-310.

44.  Zagrodzki P., Bik D., Fitak B.A., Suchocki P., Niemczuk K. Selenoenzymes in animal tissues after supplementation with SELOL. Bulletin of the Veterinary Institute in Puławy, 2000, 44(2).

45.  Barnham K. J., Masters C. L., Bush A. I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov, 2004, 3(3), 205-214.

46.  Martin H. L.,Teismann P. Glutathione--a review on its role and significance in Parkinson's disease. Faseb j, 2009, 23(10), 3263-3272.

47.  Wang A. Z., Langer R., Farokhzad O. C. Nanoparticle delivery of cancer drugs. Annu Rev Med, 2012, 63, 185-198.

48.  Poste G., Kirsh R. Site-Specific (Targeted) Drug Delivery in Cancer Therapy. Nat Biotech, 1983, 1(10), 869-878.

49.  Falqueiro A. M., Primo F. L., Morais P. C., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C. Selol-loaded magnetic nanocapsules: A new approach for hyperthermia cancer therapy. Journal of Applied Physics, 2011, 109(7), 07B306.

50.  Falqueiro A. M., Siqueira-Moura M. P., Jardim D. R., Primo F. L., Morais P. C., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C. In vitro cytotoxicity of Selol-loaded magnetic nanocapsules against neoplastic cell lines under AC magnetic field activation. Journal of Applied Physics, 2012, 111(7), 07B335.

51.  Estevanato L. L., Da Silva J. R., Falqueiro A. M., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C., Morais P. C., Lacava Z. G. Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy. Int J Nanomedicine, 2012, 7, 5287-5299.

52.  de Souza L. R., Muehlmann L. A., Dos Santos M. S., Ganassin R., Simon-Vazquez R., Joanitti G. A., Mosiniewicz-Szablewska E., Suchocki P., Morais P. C., Gonzalez-Fernandez A., Azevedo R. B., Bao S. N. PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells. J Nanobiotechnology, 2014, 12, 32.